Ascendis Pharma Unveils Bold Strategic Update at J.P. Morgan Healthcare Conference
Ascendis Pharma A/S has provided a comprehensive update on its business and strategic roadmap for 2025, highlighting key milestones and growth opportunities. This update was presented by Jan Mikkelsen, President…
Heart Failure Bayer Files FDA and CDE Applications for Finerenone’s New Indication
Introduction to Heart Failure and the Need for New Treatments Bayer has announced that it has submitted marketing authorization applications to both the U.S. Food and Drug Administration (FDA) and…
Regenerative Medicine Breakthroug Bio-Techne Expands AI-Engineered Protein Portfolio for Cell Therapy
Regenerative Medicine Revolutionary Technologies Behind the Innovation Bio-Techne a renowned global leader in life science tools and reagents, has unveiled an impressive expansion to its R&D Systems AI-engineered designer protein…
Osimertinib Compared to RYBREVANT® + LAZCLUZE™ Significant and Promising Survival Benefit Observed
Osimertinib: A Benchmark in Targeted Therapy Osimertinib The European Commission has granted approval for the combination of RYBREVANT® (amivantamab) and LAZCLUZE® (lazertinib) for the first-line treatment of adult patients with…
Promising Formulation of New Sarclisa Subcutaneous Treatment Meets Co-Primary Endpoints in IRAKLIA Phase 3
Formulation Results from the IRAKLIA Phase 3 Study Demonstrate Promise for Subcutaneous Sarclisa in Multiple Myeloma The Formulation IRAKLIA Phase 3 study has presented encouraging results for the investigational subcutaneous…
Biologics License Grifols Submits Application to U.S. FDA for Innovative Fibrinogen Solution
Biologics License Grifols Advances Fibrinogen Solution with U.S. FDA Submission Biologics License Grifols a global healthcare company and leading manufacturer of plasma-derived medicines, has announced the submission of a Biologics…
Ailux Biologics Triumphantly UCB Collaborates with XtalPi Division to Revolutionize AI-Powered Biologics
Ailux Biologics UCB\u2019s Strategic Collaboration with Ailux Biologics Ailux Biologics UCB, a leading global biopharmaceutical company, and XtalPi, an industry pioneer in AI-powered drug discovery, have announced a landmark license…
Poseida Therapeutics Roche Acquires Majority Shares in Tender Offer
Roche Acquires Poseida Therapeutics: $9.00 per Share Tender Offer Completed Poseida Therapeutics Roche a global leader in the pharmaceutical and diagnostics industries, has announced the successful completion of its tender…
Breakthrough Cardiometabolic Disease Treatments Valo Health and Novo Nordisk Expand Collaboration
Novo Nordisk and Valo Health Expand Partnership to Accelerate Cardiometabolic Disease Treatment Discovery Novo Nordisk A/S and Valo Health have announced a significant expansion of their collaboration aimed at discovering…
Groundbreaking Glucocorticoid Treatment in Congenital Adrenal Hyperplasia Neurocrine Biosciences Publishes Study $10 Million
Impact of High-Dose Glucocorticoid Therapy on Long-Term Health Neurocrine Biosciences has announced the publication of a comprehensive narrative review exploring the complexities of traditional glucocorticoid (GC) treatment for classic congenital…
Announces Breakthrough G-Rex® Grant: $125,000 Awarded to Seattle Children’s Therapeutics
Children’s Therapeutics ScaleReady Partners with Industry Leaders to Support Seattle Announces Children’s Therapeutics ScaleReady, in partnership with Wilson Wolf Manufacturing and Bio-Techne Corporation, has announced that Seattle Children’s Therapeutics, a…
Malaria WHO Approves Breakthrough Test for Safer P. vivax Treatment
The Role of G6PD Testing in Malaria Treatment On December 18, 2024, the World Health Organization (WHO) achieved a groundbreaking milestone by prequalifying the first diagnostic test for glucose-6-phosphate dehydrogenase…